Navigation Links
Soligenix to Present at 12th Annual BIO CEO & Investor Conference
Date:2/3/2010

acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host-Disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD and an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Both of these trials are actively enrolling patients. Soligenix has also recently initiated an NIH-supported Phase 1/2 clinical trial of SGX201 in the prevention of acute radiation enteritis. Additionally, Soligenix has a Lipid Polymer Micelle (LPM™) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, Soligenix is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. Soligenix's lead biodefense product in development is a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin. RiVax™ has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. RiVaxTM will also be the subject of a recent $9.4 million NIH grant received by the Company supporting development of new heat stable vaccines.

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical fa
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Soligenix Reports Third Quarter 2009 Financial Results
2. Soligenix to Present at 8th Annual BIO Investor Forum
3. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
4. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
5. Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
6. ERT to Present at the UBS 20th Annual Global Healthcare Services Conference on February 8, 2010
7. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
8. Telik Announces Presentation and Webcast at 12th Annual BIO CEO & Investor Conference
9. NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010
10. NeurogesX to Present at J.P. Morgan Health Care Conference
11. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  On May ... FCN ), the global business advisory firm dedicated ... value (the "Company"), announced that it has combined ... were formerly included within the Corporate Finance/Restructuring segment ... segment to form a single integrated practice whose ...
(Date:5/21/2013)... 2013 Alpha Source, Inc., a ... be exhibiting for the 13th consecutive year at ... (AAMI) 2013 Conference and Expo. The conference brings ... manufacture healthcare technologies. This year’s event will be ... , The three-day event draws over 1,500 ...
(Date:5/21/2013)... ALBANY, New York , May 21, 2013 /PRNewswire/ ... published by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip ... Science Research, IVD Tests) - U.S. Industry Analysis, Size, Share, ... USD 2.4 billion in 2011 and is expected to ... 2018, to reach an estimated value of USD 4.7 ...
(Date:5/21/2013)... 21, 2013  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... serious infectious diseases, announced today that Jeffrey Riley ... Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 ... Grand Hyatt Hotel. Mr. Riley is scheduled to present at ... Synthetic Biologics, presentation can be accessed by logging onto the ...
Breaking Biology Technology:FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2
... the more difficult challenges in business is turning around a ... and the company is forced into bankruptcy. Realizing the painful ... or impossible for owners and senior executives to deal with ... save them, and they will close that big outstanding proposal, ...
... escalate at a double-digit pace in 2003, but there are ... next year, according to global HR outsourcing and consulting firm ... 12.6 percent average increase for employers, which is lower than ... to absorb the majority of next year's increase, but many ...
... business conditions provide a golden opportunity to tune your ... appear to have calmed, the long-term winners will be ... winning strategies. Real competitive advantage comes from making ... fundamentally aligning your talent management practice to that choice, ...
Cached Biology Technology:Turning Around a Sick Company 2Health Care Costs Continue Double-Digit Pace, But May Start Moderating in 2004 2Health Care Costs Continue Double-Digit Pace, But May Start Moderating in 2004 3Talent Constellations or Talent Communities Choosing the Right Talent 2Talent Constellations or Talent Communities Choosing the Right Talent 3
(Date:5/22/2013)... Lung Screening Trial (NLST) investigators also conclude that ... with low-dose computed tomography (LDCT) versus chest X-ray ... paper is achievable at experienced screening centers in ... information to share with their patients about the ... following today,s publication in the New England ...
(Date:5/22/2013)... can detect molecular variants in chemical mixtures greatly ... important, though time-consuming, processes in analytical chemistry. , ... post-doctoral researcher David Patterson, Professor of Physics John Doyle ... Laser Science (CFEL) in Hamburg, Germany developed a system ... variants apart, and to determine how much variant is ...
(Date:5/22/2013)... fatty acids in fish oil have long been thought ... American Heart Association currently recommends eating at least two ... in omega 3s. However, the mechanism behind this protective ... scientists led by Jason R. Carter of Michigan Technological ... that fish oil might specifically counteract the detrimental effects ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Detecting mirror molecules 2Detecting mirror molecules 3Fish oil may help the heart beat mental stress 2
... living in the deep sea, it seems that there is ... it,s generally best to be transparent. But in the deeper ... as searchlights, it,s much better to go in darker colors. ... 10 in Current Biology , a Cell Press publication. ...
... 10, 2011 ─ (BRONX, NY) ─ Researchers at then ... Yeshiva University have uncovered a mechanism that governs how ... implications for human health and disease and appear in ... Cell . A fundamental question in biology ...
... weed that clogs waterways around the world has at least ... for boats and submarines. The Brazilian fern Salvinia ... part because its surface is dotted with oddly shaped hairs ... afloat. In the November 1 issue of the ...
Cached Biology News:For deep-sea cephalopods, 'switchable' camouflage saves the day 2Einstein researchers discover key to cell specialization 2Plant with 'eggbeater' testure inspires waterproof coating 2Plant with 'eggbeater' testure inspires waterproof coating 3
... Red, 20X Immunogen ... 20X concentration for use in KinEASE™ ... Quality Assurance Routinely ... polarization assays. Stability ...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: